The adipose tissue production of adiponectin is increased in end-stage renal disease. by Martinez Cantarin, Maria P et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medicine Faculty Papers Department of Medicine
3-1-2013
The adipose tissue production of adiponectin is
increased in end-stage renal disease.
Maria P Martinez Cantarin
Thomas Jefferson University, Clinical Pharmacology and Experimental Therapeutics; Department of Medicine, Thomas Jefferson
University, Maria.MartinezCantarin@jefferson.edu
Scott A Waldman
Thomas Jefferson University, Clinical Pharmacology and Experimental Therapeutics, scott.waldman@jefferson.edu
Cataldo Doria
Department of Surgery, Thomas Jefferson University, cataldo.doria@jefferson.edu
Adam M Frank
Department of Surgery, Thomas Jefferson University, adam.frank@jefferson.edu
Warren R Maley
Department of Surgery, Thomas Jefferson University, Warren.Maley@jefferson.edu
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/medfp
Part of the Nephrology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Martinez Cantarin, Maria P; Waldman, Scott A; Doria, Cataldo; Frank, Adam M; Maley, Warren R;
Ramirez, Carlo B; Keith, Scott W; and Falkner, Bonita, "The adipose tissue production of
adiponectin is increased in end-stage renal disease." (2013). Department of Medicine Faculty Papers.
Paper 110.
http://jdc.jefferson.edu/medfp/110
Authors
Maria P Martinez Cantarin, Scott A Waldman, Cataldo Doria, Adam M Frank, Warren R Maley, Carlo B
Ramirez, Scott W Keith, and Bonita Falkner
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/medfp/110
The adipose tissue production of adiponectin is increased in
end stage renal disease
Maria P Martinez Cantarin, MD1,3, Scott Waldman, MD, PhD1, Cataldo Doria, MD, PhD2,
Adam M. Frank, MD2, Warren R. Maley, MD2, Carlo B. Ramirez, MD2, Scott W. Keith, PhD1,
and Bonita Falkner, MD3
1Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University,
Philadelphia, PA
2Department of Surgery, Thomas Jefferson University, Philadelphia, PA
3Department of Medicine, Thomas Jefferson University, Philadelphia, PA
Abstract
Adiponectin has anti-diabetic properties and patients with obesity, diabetes and insulin resistance
have low plasma adiponectin levels. However, although kidney disease is associated with insulin
resistance, adiponectin is elevated in end stage renal disease. Here we determine if adipose tissue
production of adiponectin is increased in renal disease in a case-control study of 36 patients with
end stage renal disease and 23 kidney donors. Blood and tissue samples were obtained at kidney
transplantation and donation. The mean plasma adiponectin level was significantly increased to
15.6 mg/ml in cases compared to 8.4 mg/ml in controls. Plasma levels of the inflammatory
adipokines tumor necrosis factor α, interleukin 6 and high sensitivity C-reactive protein were
significantly higher in cases compared to controls. Adiponectin mRNA and protein expression in
visceral and subcutaneous fat was significantly higher in cases than controls while adiponectin
receptor 1 mRNA expression was significantly increased in peripheral blood cells, muscle and
adipose tissue in cases compared to controls. Thus, our study suggests that adipose tissue
production of adiponectin contributes to the high plasma levels seen in end stage renal disease.
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Introduction
Adiponectin is a protein produced primarily by adipocytes from white and brown adipose
tissue(1). Adipose tissue also produces several other pro-inflammatory cytokines and
hormones including plasminogen activator inhibitor-1 (PAI-1), interleukin 6 (IL-6), tumor
necrosis factor alpha (TNFα), leptin and resistin, but adiponectin is the most abundant (2).
Other tissues such as the myocardium (3), skeletal muscle (4), liver (5), bone (6) and
salivary gland (7) also have the capacity to produce adiponectin. Adiponectin production by
non-adipose tissue is markedly lower than in fat and is unlikely to contribute significantly to
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plasma levels. Adiponectin levels in plasma vary from 2–30 mg/L representing 0.01% of the
total plasma protein (8). Full length adiponectin is found as different multimers in human
plasma: the low molecular weight trimer (LMW) that consists of 3 adiponectin molecules
that bind through their collagen domain is the most abundant form of adiponectin in plasma.
There is also a middle molecular weight (MMW) hexamer and the HMW isoform that is
composed of multiple species depending on the number of adiponectin molecules that are
associated (9, 10). Although little is known about adiponectin’s isoform function, HMW
adiponectin seems to be the more biologically active component (10).
Adiponectin has two membrane receptors: Adiponectin Receptor-1 and Adiponectin
Receptor-2 (AdipoR1, AdipoR2) (11). These are ubiquitously expressed in human tissues,
but more predominantly in muscle and liver where they exert their major antidiabetic
functions. Based on rodent experiments, adiponectin appears to have anti-diabetic, anti-
atherogenic and anti-inflammatory properties (12). These findings are consistent with human
clinical data which show an association between low plasma adiponectin levels and obesity,
insulin resistance, metabolic syndrome and diabetes mellitus (12). Low adiponectin levels in
humans have also been associated with increased atherosclerotic cardiovascular events,
hypertension and dyslipidemia (13).
Contrary to expectations, plasma adiponectin levels are high in chronic kidney disease
(CKD) (14) and end stage renal disease (ESRD) (15) despite greater insulin resistance (16),
cardiovascular disease and dyslipidemia (17). Levels of the HMW adiponectin isoform are
also elevated in ESRD although the distribution of all the adiponectin isoforms in chronic
kidney disease and ESRD has not been well studied (18).
The underlying cause for the higher levels of circulating adiponectin in kidney disease is
still unclear (14). It has been suggested that decreased renal clearance is the cause of
increased plasma levels of adiponectin in patients with failing kidney function (19). We
postulate that the cause may be adiponectin resistance, with an abnormal receptor-ligand
interaction, or augmented adiponectin production secondary to chronic inflammation. There
is currently no definitive data to favor one hypothesis over the other.
Cardiovascular disease (CVD) is the leading cause of death in CKD patients (17).
Nontraditional CVD risk factors such as vascular calcification, inflammation, oxidative
stress and endothelial dysfunction (20) may contribute to CVD development in CKD
patients. An abnormal pattern of adipokines, including both adiponectin as well as pro-
inflammatory cytokines, are factors that may also contribute to CVD. Although adiponectin
levels are higher in CKD patients compared to those with normal kidney function, within the
CKD population relatively low levels of adiponectin are predictive of poor CVD outcomes
(15) and are inversely related to glucose abnormalities (21). Moreover, both subcutaneous
and visceral adipose tissues from patients with ESRD express higher levels of pro-
inflammatory cytokines (22). Increased expression of inflammatory cytokines may
contribute significantly to the chronic inflammatory state of uremia and subsequently play a
role in CVD risk.
Further delineation of the adiponectin axis in CKD is needed to delineate the function and
regulation of this hormone in ESRD patients and its relationship to insulin sensitivity and
CVD. The purpose of this study was to determine whether there is greater adiponectin and
adiponectin receptor production in tissues, including visceral fat, subcutaneous fat, and
muscle, of ESRD patients compared to healthy controls. We also compared plasma levels of
adiponectin and proinflammatory cytokines in these ESRD patients and healthy controls.
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Results
Participants Characteristics
Our study sample included 36 ESRD patients and 23 controls. The clinical characteristics of
the study population are highlighted in Table 1. The mean age of the ESRD cohort was 50
years and the controls were younger, with a mean age of 41 years. There were more females
in the control group (65% versus 33% in the ESRD group). The mean body mass index
(BMI) of the ESRD cases was 27 kg/m2 and 25 kg/m2 for the controls. In our study sample,
59% of the ESRD and 74% of the controls were white. Fasting blood sugar was significantly
higher in the ESRD group than in the control group. In the ESRD group, 70% were
receiving renal replacement therapies (4 patients receiving peritoneal dialysis and 22
receiving hemodialysis), 38% had DM, 8% had hepatitis C virus infection, and 16% had a
prior kidney transplant. The main cause of kidney disease in our ESRD cases was DM and
hypertension (47%) followed by glomerulonephritis (31%), polycystic kidney disease (11%)
and miscellaneous causes of ESRD (11%)
Plasma Adipokine Levels
Table 2 shows the plasma adipokine values in our study groups. All the inflammatory
adipokines, except PAI-1, were significantly higher in ESRD cases even after stratification
for DM status (p<0.001 for all). Adiponectin was also significantly higher in ESRD patients
compared to controls (P=0.001). In addition, subgroup analysis demonstrated significantly
higher adiponectin in both nonDM (P=0.05) and DM ESRD subjects (P<0.001) compared to
controls. The DM ESRD cases had the highest levels of adiponectin, IL-6 and hsCRP.
Women had higher adiponectin levels than men (14.94±9.2 versus 11.59±7.72 respectively,
p=0.14) which is consistent with the expected sexual dimorphism of the hormone. On
further stratification by our study groups, women continue to have higher adiponectin levels
than men although the differences were statistically significant only in the DM ESRD cases
(control males 6±4.25 versus females 9.77±4.53, p=0.08; nonDM ESRD cases-males
12.19±7.79 versus females 15.7±8.71, p=0.37; and DM ESRD cases-males 14.94±7.94
versus females 25.4±8.95, p=0.03). The peritoneal dialysis participants had higher
adiponectin levels than the hemodialysis patients but the difference was not statistically
significant (19.6±8.7 versus 15.1±9.1, p= 0.36). Further analysis using linear regression
models with adjustment for obesity and renal function again revealed that IL-6, TNFα,
hsCRP, as well as adiponectin were significantly higher in the ESRD group compared with
the control group independent of obesity status (p<0.001 for IL-6 and adiponectin, p=0.007
for TNFα, and p=0.001 for hsCRP). Alternatively, when all participants (both ESRD and
controls) were stratified according to BMI status (normal weight, overweight, obese), the
overweight or obese participants have higher inflammatory cytokines and lower adiponectin
compared to participants of normal weight independent of their renal function status (P<0.05
for adiponectin; P<0.05 for hsCRP).
Adiponectin and AdipoR mRNA expression levels in Tissue and blood
Figures 1–3 depicts the mRNA expression of adiponectin and the AdipoR1/2 in visceral fat,
subcutaneous fat, muscle and peripheral blood mononuclear cells (PBMN) in ESRD cases
and controls. In visceral fat, adiponectin mRNA expression was 40% higher in nonDM
ESRD cases than in controls. AdipoR1 mRNA expression was 20% higher in nonDM ESRD
cases and 30% higher in DM ESRD cases than controls. AdipoR2 was 30% lower in DM
ESRD cases than controls. In subcutaneous fat, adiponectin mRNA expression was 20%
higher in nonDM ESRD cases than controls; AdipoR1 was 20% higher in nonDM ESRD
cases and 30% higher in DM ESRD cases than controls. Skeletal muscle of ESRD patients
showed a 30% higher mRNA expression of AdipoR1 than controls. The largest differences
in mRNA expression of adiponectin receptors were seen in peripheral blood where the
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expression of AdipoR1 in nonDM ESRD cases was 70% higher and the expression in DM
ESRD cases was 140% higher than controls while AdipoR2 was 25% higher in nonDM
ESRD cases than controls. There were no significant differences in the expression of
AdipoR2 in subcutaneous fat or muscle in ESRD patients compared to controls (data not
shown). Therefore, AdipoR1 mRNA expression was consistently higher in all tissues of
ESRD patients compared to controls, whereas there was no consistent pattern detected for
AdipoR2.
Overall, adiponectin and AdipoR1 mRNA expression in visceral and subcutaneous fat were
significantly greater in ESRD cases compared to controls, independent of their DM status
(p<0.005 for all). There was also a significant increase in the expression of the AdipoR1 in
muscle of ESRD cases compared to controls (p<0.001). Both AdipoR1 and AdipoR2 mRNA
expression were significantly higher in PBMN of ESRD cases compared with controls but
the difference was greatest in ESRD DM cases (p<0.001).
Adiponectin Protein Expression in Adipose Tissue
Adipose tissue adiponectin protein content by western blot is shown in Figure 4. Both
visceral fat and subcutaneous fat adiponectin protein expression were higher in the ERSD
cases than in controls with normal kidney function.
Discussion
We show for the first time that increased plasma adiponectin levels observed in ESRD are
accompanied by an increase in adiponectin protein and mRNA expression in human
subcutaneous and visceral adipose tissue. Our data also demonstrate that mRNA expression
of the adiponectin receptor is increased in the target tissues, fat and muscle, in ESRD
patients compared to controls with normal kidney function. Our data also detected a
difference in plasma adiponectin levels between ESRD patients with and without DM.
Increased adiponectin mRNA expression and protein content in adipose tissue suggests that
decreased renal clearance of adiponectin may not be the only factor contributing to elevated
circulating levels in subjects with chronic kidney disease. Under normal conditions (non-
obese, non-diabetic and normal kidney function), chronic expression of adiponectin in
adipose tissue results in down-regulation of adiponectin mRNA expression in adipose tissue
and lowered plasma levels (23). These findings indicate that adiponectin follows the
common hormone-receptor interaction axis, where the increase in circulating hormone levels
triggers down-regulation of hormone production in order to resume baseline circulating
protein levels. If decreased clearance were the main cause of elevated adiponectin
circulating levels, we should see a decrease in hormone production by the adipose tissue.
Reports that describe a correlation between adiponectin levels and estimated glomerular
filtration rate (eGFR) (14) or a decrease in adiponectin levels after kidney transplantation
(24, 25) have not demonstrated a direct effect of renal clearance on adiponectin levels. On
the other hand, studies that include direct measurement of adiponectin in plasma from the
aorta and renal veins of patients with renal artery stenosis demonstrate that the fractional
extraction of adiponectin is low, around 3 to 5%, with similar findings when adiponectin
extraction rates are compared in a kidney with renal artery stenosis to the contralateral non-
diseased kidney (26). Previous reports also show that adiponectin is rapidly cleared from
plasma with a short half-life (75min) and that the liver seems to be the primary clearance
site as the kidney excretes only terminal degradation products (27). Data from our study
support the hypothesis that increased production of adiponectin contributes to increased
adiponectin plasma levels. Therefore it is unlikely that decreased renal clearance is the only
cause of elevated plasma adiponectin levels in patients with ESRD.
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Our data demonstrate higher levels of both anti-inflammatory and inflammatory adipokines
in ESRD patients compared to controls. These findings may reflect the adiponectin response
to the inflammatory environment that characterizes uremia. Pro-inflammatory cytokines
such as TNFα, IL-6, and interleukin 8 (IL-8) have been shown to down-regulate adiponectin
expression (28) but high levels of adiponectin have been described in other chronic
inflammatory states such as systemic lupus erythematosus, rheumatoid arthritis,
inflammatory bowel disease, type I diabetes and chronic systolic heart failure (29).
Therefore, it remains unclear whether an inflammatory condition directly up-regulates or
down-regulates adiponectin production or if there are other mediators associated with
chronic inflammation that regulate adiponectin production.
There are functional differences between AdipoR1 and R2 receptors. In liver tissue,
AdipoR1 down regulates genes associated with hepatic gluconeogenesis while AdipoR2 up
regulates genes involved in glucose uptake and reduces reactive oxygen species and
inflammation (30). Insulin resistance in uremia is mainly characterized by peripheral tissue
insensitivity to insulin with normal hepatic gluconeogenesis and normal uptake of glucose
by the liver (16). In the current study, we find increased tissue AdipoR1 expression. If the
increased AdipoR1 inhibits liver gluconeogenesis this could partially explain why patients
with renal disease have increased insulin resistance but gluconeogenesis in the liver is not
increased. AdipoR2 expression levels in ESRD are similar to that of controls. Subjects with
ESRD have chronic inflammation with increased oxidative stress and the fact that AdipoR2
is not increased suggests a lack of a compensatory increase in AdipoR2 expression in face of
high oxidative stress. Increased oxidative stress has also been associated with insulin
resistance (31, 32). Thus adiponectin resistance with high levels of adiponectin but relatively
low AdipoR2 may contribute to the inflammatory state and insulin resistance seen in ESRD
patients.
Our data on tissue gene expression are not entirely consistent with a previous report by
Marchlewska et al. (33). These investigators studied adiponectin mRNA expression in
adipose tissue of 18 ESRD patients including 9 with atherosclerotic vascular disease and a
small sample of controls. Therefore there was an overrepresentation of ESRD patients with
cardiovascular disease. They reported a decrease in adiponectin gene expression in
subcutaneous fat tissue of patients with ESRD. Because low adiponectin levels are
associated with worse cardiovascular outcomes (34), it is possible that their study selected
ESRD participants with a CVD phenotype that is associated with lower adiponectin. Our
study population differs significantly from their study participants. We enrolled patients
with stage 5 chronic kidney disease, including dialysis patients of different vintage, without
specific risk stratification for CVD. Our participants underwent kidney transplantation and
were considered intermediate risk for CV events in the immediate post-transplant period per
AHA criteria (35). Our results are more consistent with the data by Roubicek et al. (22) that
showed an increase in AdipoR1 in visceral fat. In addition, the number of ESRD patients in
our study is significantly larger. This enabled us to detect differences in adiponectin
expression between visceral and subcutaneous adipose tissue of cases and controls.
Our data demonstrates an increase in adiponectin mRNA and protein production by adipose
tissue despite elevated circulating adiponectin levels in subjects with ESRD compared to
controls. These results suggest that there is a stimulus to produce more adiponectin protein
despite elevated plasma levels. The mechanism for increased adiponectin production in
ESRD is currently unclear. However, our data are consistent with the theory that there is
tissue resistance to adiponectin at the level of the hormone-receptor interaction or in the
downstream effectors. Adiponectin resistance has been suggested in obesity related insulin
resistance and also in chronic heart failure (12, 36). However, unlike ESRD, in obesity
related insulin resistance there is a decrease in the levels of circulating adiponectin as well as
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a reduction in adiponectin receptors in adipose and muscle tissues with decreased
downstream adiponectin effectors in muscle (12). In chronic heart failure, the elevated
adiponectin circulating levels are accompanied by decreased expression of adiponectin
receptors and downstream adiponectin effectors in skeletal muscle (36). Another possible
explanation for the increase in adiponectin production could be up-regulation of adiponectin
expression in response to non-adipose tissue derived inflammation or in response to a
uremia mediated metabolic toxin independent of inflammation.
Our data also describe an increase in adiponectin receptor-1 expression in visceral fat and
muscle of ESRD patients. Consequently, adiponectin resistance could be either at the
receptor-ligand interaction or in the downstream effectors of adiponectin signaling.
Our study has some limitations. Our data are derived from a cross-sectional study that
examined adipokine levels and adipose tissue adiponectin expression at one time point in a
chronic disease state. This limits our data to associations. We did not adjust p-values for the
possible inflation of false-positive error rates that could result from conducting multiple
tests. However, a Bonferroni correction to the significance level (p< 0.01) for the five
inflammatory adipokines tested (Table 2) will not change our conclusions, except that IL-6
falls to the borderline of the rejection region for the comparison of controls to all cases. Our
study groups were not perfectly balanced. More controls were females with lower BMI and
our cases were more frequently men with higher BMI. The distributions of our ESRD and
control samples resemble the ESRD population and the kidney donor population in the U.S.
(17, 32). Since females and leaner individuals will have higher adiponectin levels, imbalance
in the groups has likely shifted our results towards the null hypothesis compared to a study
where cases and controls were matched. Despite that, we were able to find statistically
significant differences in the plasma adiponectin values. More balanced groups may show
bigger differences in plasma and tissue adipokine levels between the groups, but the
conclusion of the study would likely be similar. We did not study adiponectin isoforms to
determine whether elevated circulating adiponectin or tissue production is limited to a
particular fraction such as the high molecular weight isoform. Due to the limited number of
participants, we were unable to stratify the sample for cardiovascular risk or glucose
tolerance. On the other hand our data represents the largest case control study to investigate
visceral fat, subcutaneous fat, and muscle tissue expression of adiponectin and adiponectin
receptors in ESRD patients and healthy controls. Our data should be considered as
groundwork in the study of adiponectin metabolism in kidney disease as the mRNA
expression analysis and tissue protein level analysis will need to be validated in larger study
samples from similar populations and also in participants with different stages of chronic
kidney disease.
In summary, patients with ESRD have elevated circulating levels of both inflammatory
adipokines and the anti-inflammatory cytokine adiponectin. Concurrently, ESRD patients
express increased adiponectin mRNA and protein expression in visceral and subcutaneous
fat than control subjects with normal kidney function. Adiponectin receptor 1 mRNA
expression in target tissues is also increased in ESRD, whereas expression of adiponectin
receptor 2 does not appear to be modified by uremia. It remains unclear if adiponectin is
functionally active in ESRD and if the elevated levels of adiponectin are a compensatory
mechanism for adiponectin resistance or a response to chronic inflammation. Further studies
to unravel regulation and function of adiponectin in renal disease will be needed to assess
this adipokine’s role in cardiovascular disease and glucose abnormalities in patients with
kidney disease.
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Methods
Design and Subjects
We designed a case control study to compare adipokine plasma levels and adiponectin and
adiponectin receptor mRNA and protein expression in adipose tissue of ESRD patients
compared to healthy controls. Participants were recruited from the Thomas Jefferson
University Hospital (TJUH) transplant program from August 2010 until August 2011.
Criteria for inclusion in the study included undergoing kidney transplantation or kidney
donation at TJUH. ESRD subjects on renal replacement therapy or CKD stage 5 pre-renal
replacement therapy were included as cases. The control group consisted of normal renal
function kidney donors. Multi-organ transplants and subjects with a functional pancreas
transplant were excluded. Cases were further stratified into 2 groups: subjects without
diabetes (DM) prior to transplantation were designated NonDM ESRD cases and subjects
with diabetes before transplant were designated DM ESRD cases. Subjects were classified
as diabetics prior to transplantation if diabetes was the cause of kidney disease or a co-
morbidity at the time of transplant, if the patient was receiving treatment for diabetes pre-
transplant, and if laboratory values were diagnostic of DM as per ADA criteria (37). The
study protocol was approved by the Institutional Review Board at TJU and written informed
consent was obtained from every subject.
Demographic data and baseline characteristics were obtained from the medical records at the
time of admission for surgery. Plasma was obtained fasting the morning of transplantation or
donation.
Procedures
Total plasma adiponectin, IL-6, high sensitivity C-reactive protein (hsCRP), TNFα, and
PAI-1 assays were carried out by ELISA, utilizing a commercial kit from R&D Systems
(Minneapolis MN) and Hyphen Biomed (Elitest PAI-1, Mason, OH). The intra-assay
coefficient of variation (c.v.) was < 10% and inter-assay c.v. was also < 10% for each of the
cytokines. While participants were under general anesthesia, approximately 250 mg of
omental visceral fat and subcutaneous fat from just below the abdominal skin and 100 mg of
skeletal muscle from the rectus abdominis were obtained. Around 100 mg of adipose tissue
and 50 mg of muscle were submerged in RNAlater (Ambion, Carlsbad, CA) and blood was
stored in Paxgene blood RNA tubes (Preanalytix, Hombrechtikon, Switzerland). RNA
extraction from blood was performed with Paxgene blood RNA kit (Preanalytix,
Hombrechtikon, Switzerland) and RNA extraction from tissue was performed with RNeasy
Lipid Tissue Mini Kit (Qiagen, Valencia, CA). Adiponectin, AdipoR1 and AdipoR2 mRNA
differential expression was performed by TaqMan Assays-on-Demand (Applied Biosystems,
Foster City, CA, USA). Reverse transcription was performed in a thermal cycler under
universal conditions. For the real time reaction, template cDNA was mixed with TaqMan
Gene Expression Assays for Adiponectin, AdipoR1, AdipoR2 and GAPDH as control gene
and TaqMan Gene Expression Master Mix containing AmpliTaq Gold enzyme (Applied
Biosystems, Foster City, CA). The reactions were run on the Applied Biosystems 7500
Sequence Detection System under universal cycling conditions. cDNA from one of the
controls was serially diluted to generate a standard curve for each set of gene primers and
tissue. Standard curve and samples were run in triplicate. The relative values for the samples
were determined by plotting the sample log cDNA dilution versus the Ct value on the
standard curve. The final expression value was normalized to GAPDH. Data are presented
as the average ratios of target mRNA to a reference gene in tissue in arbitrary units. 150 mg
of subcutaneous and visceral fat tissue form ESRD cases and controls were homogenized in
400 ul of cold lysis buffer containing 1M Tris, 250 mM DTT, 250mM PMSF, 250mM
EDTA and 250mM EGTA. The homogenate was spun at 3000 rpm for 10 minutes at 4C and
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the middle layer was retrieved for protein quantification using the Bradford method (BioRad
laboratories, Hercules, CA). 20 ug of sample was mixed with 4X NuPAGE LDS sample
buffer (Life Technologies, Grand Island, NY) and mercaptoethanol and loaded in a
polyacrylamide gel (NuPAGE Novex 4–12% Bis Tris gels, Life Technologies, Grand Island,
NY) under reducing and heated conditions. Proteins were then transferred to a
polyvinylidene fluoride membrane (Life Technologies, Grand Island, NY) and, after
transfer, membranes were blocked with 5% bovine serum albumin. Membranes were
incubated with the primary antibody (Adiponectin 1:200 and actin 1: 500 both from Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4° C. Horseradish peroxidase conjugate
secondary antibodies were incubated for 1 hour and immunoreactivity for adiponectin and
controls was detected by an enhanced chemiluminescence system (SuperSignal West Dura
Chemiluminescent Substrate, Thermo Scientific, Rockford, IL).
Data Analysis
Continuous and categorical data were analyzed. The variables were generally summarized in
terms of arithmetic means and standard deviations or counts and percentages. Most of the
continuous data variables were approximately normally distributed. IL-6 was substantially
skewed, but was approximately normally distributed after log transformation prior to
statistical testing. IL-6 data was summarized by geometric mean (GM) with first and third
quartiles of the untransformed data. To test for differences in means across the cases and
control groups, unadjusted analysis of variance (ANOVA) F-tests and t-tests were conducted
on continuous variables. Fisher’s exact test was used to detect dependencies between
categorical variables. Student t-test was used to compare differences in mRNA expression
between cases and controls. Linear regression models were fitted in order to investigate how
cytokines relate to obesity and renal status. All statistical analyses were conducted using
SAS version 9.2 (SAS Institute, Cary, NC, USA).
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Figure 1. Adiponectin mRNA expression in adipose tissue
Panel A. Visceral Fat. Panel B. Subcutaneous fat. Controls are compared with ESRD on
RRT or CKD5 pre-RRT (cases). Cases are stratified by diabetes status in non-diabetics
(NonDM) or diabetics (DM).* p<0.005, Student’s t test.
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Figure 2. Adiponectin receptor 1 (AdipoR1) mRNA expression in tissue and blood
Panel A Visceral adipose tissue, Panel B Subcutaneous adipose tissue, Panel C Skeletal
muscle, Panel D Peripheral blood mononuclear cells. Controls are compared with ESRD
cases. Cases are stratified by diabetes status in non-diabetics (NonDM) or diabetics (DM).
*p<0.001, **p<0.05, Student’s t test.
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Figure 3. Adiponectin receptor 2 (AdipoR2) mRNA expression in tissue and blood
Panel A; Visceral adipose tissue, Panel B; Peripheral blood mononuclear cells. Controls are
compared with ESRD cases. Cases are stratified by diabetes status in non-diabetics
(NonDM) or diabetics (DM).* p value <0.01, Student’s t test.
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Figure 4. Adiponectin protein content in adipose tissue
Visceral and subcutaneous adipose tissue was obtained at the time of kidney transplantation
or kidney donation in ESRD cases and controls. Panel A: representative western blot of
adiponectin content in subcutaneous fat compared with control tubulin in controls versus
ESRD cases. Panel B: representative western blot of adiponectin content in visceral fat
compared with control actin in controls versus ESRD cases.
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Table 1
Baseline characteristics of study subjects
Variable
Controls ESRD (Cases)
(N=23) All (N=36) NonDM (N=21) DM (N=15)
Age (yrs) 41.9 (10.63) 50.27 (12.45) 45 (12.3) 57.1 (9.2)
Sex (female) 15 (65) 12 (33) 6 (28) 6 (40)
Height (inch) 68.16 (4.87) 67.21 (4.69) 68.14 (5.7) 68.2 (3.4)
Weight (lb) 167.69 (32.38) 183.63 (41.52) 184.3 (42) 182.6 (37.9)
BMI (kg/m2) 25.87 (4.01) 27.27 (4.42) 27.1 (4.7) 27.4 (4.1)
   Normal 10 (45%) 10 (28%) 6 (29%) 4 (27%)
   Overweight 10 (45%) 13 (36%) 9 (43%) 4 (27%)
   Obese 3 (10%) 13 (36%) 6 (29%) 7 (47%)
Race
   White 17 (74%) 21 (59%) 15 (71%) 6 (40%)
   Black 4 (17%) 12 (34%) 4 (19%) 8 (53%)
   Other 2 (9%) 3 (7%) 2 (10%) 1 (7%)
FBS (mg/dl) 85.14 (10.7) 108.13 (43.12) 90.6 (6.5) 132.6 (59)
Creatinine (mg/dl) 0.76 (0.12) 6.89 (2.67) 7 (2.9) 6.5 (2)
Ccr(ml/min) a 127.46 (26.28) 11 (3.55) 11.1 (3.9) 10.5 (2.1)
Categorical Variables: Frequencies (Percents), Continuous Variables: Mean (SD) BMI: Body mass index, FBS: fasting blood sugar, Ccr Creatinine
Clearance
aClearance in controls measured by 24h urine collection, in cases by MDRD equation
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Table 2
Cytokines for diabetic and non-diabetic cases and controls (N=59)
Variable
Controls ESRD (Cases)
(N = 23) All (N=36) NonDM (N = 21) DM (N = 15)
Adiponectin (ug/ml) 8.46 (4.70) 15.66 (9) 13.20 (8.01) 19.13 (9.64)
p value 0.001a 0.001b
IL-6 (pg/ml)c 2.9 [2.1, 2.9] 6.2 [3.8, 10.4] 5.3 [3.4, 6.7] 7.9 [4.3, 16.0]
p value 0.02a <0.001b
PAI-1 (ng/ml) 50.60 (19.7) 44.63 (22.67) 47.73 (25.1) 40.30 (17.8)
p value 0.30a 0.30b
TNFα (pg/ml) 10.17 (3.35) 19.17 (12.14) 21.12 (15.2) 16.46 (4.88)
p value 0.002 a <0.001b
hsCRP (mg/dl) 1.26 (0.94) 4.16 (3) 3.61 (2.94) 4.94 (3.18)
p value <0.001 a <0.001b
Continuous Variables: Mean (SD) or Geometric Mean [1st quartile, 3rd quartile]
a
t test: differences between controls and all cases.
bANOVA F-test: any groups different (3-way comparison test: controls vs nonDM cases vs DM cases)
c
Data natural log transformed: geometric means with [first quartile, third quartile] presented
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